Your 2nd reference talks about the theoretical lowest price that a hypothetical manufacturer could manufacture longer-acting insulins at. It doesn't identify any manufacturer actually producing at those prices.
Scoundreller wanted a manufacturer producing "the newer biosimilar insulin for just $72-133 per year". That link doesn't appear to provide that information.
